These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21537084)

  • 1. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
    Aucagne R; Droin N; Paggetti J; Lagrange B; Largeot A; Hammann A; Bataille A; Martin L; Yan KP; Fenaux P; Losson R; Solary E; Bastie JN; Delva L
    J Clin Invest; 2011 Jun; 121(6):2361-70. PubMed ID: 21537084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
    Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
    Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TIF1γ: a tumor suppressor gene in chronic myelomonocytic leukemia].
    Aucagne R; Droin N; Solary E; Bastie JN; Delva L
    Med Sci (Paris); 2011; 27(8-9):696-8. PubMed ID: 21880252
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
    Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
    Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
    Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
    J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
    Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
    Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult hematopoiesis is regulated by TIF1γ, a repressor of TAL1 and PU.1 transcriptional activity.
    Kusy S; Gault N; Ferri F; Lewandowski D; Barroca V; Jaracz-Ros A; Losson R; Romeo PH
    Cell Stem Cell; 2011 Apr; 8(4):412-25. PubMed ID: 21474105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
    Carr RM; Patnaik MM
    Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
    Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The zebrafish moonshine gene encodes transcriptional intermediary factor 1gamma, an essential regulator of hematopoiesis.
    Ransom DG; Bahary N; Niss K; Traver D; Burns C; Trede NS; Paffett-Lugassy N; Saganic WJ; Lim CA; Hersey C; Zhou Y; Barut BA; Lin S; Kingsley PD; Palis J; Orkin SH; Zon LI
    PLoS Biol; 2004 Aug; 2(8):E237. PubMed ID: 15314655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat chronic myelomonocytic leukemia.
    Solary E; Itzykson R
    Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia.
    Zheng S; Ma X; Zhang L; Gunn L; Smith MT; Wiemels JL; Leung K; Buffler PA; Wiencke JK
    Cancer Res; 2004 Mar; 64(6):2000-6. PubMed ID: 15026336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes.
    Bai X; Trowbridge JJ; Riley E; Lee JA; DiBiase A; Kaartinen VM; Orkin SH; Zon LI
    Dev Biol; 2013 Jan; 373(2):422-30. PubMed ID: 23159334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
    Merlevede J; Droin N; Qin T; Meldi K; Yoshida K; Morabito M; Chautard E; Auboeuf D; Fenaux P; Braun T; Itzykson R; de Botton S; Quesnel B; Commes T; Jourdan E; Vainchenker W; Bernard O; Pata-Merci N; Solier S; Gayevskiy V; Dinger ME; Cowley MJ; Selimoglu-Buet D; Meyer V; Artiguenave F; Deleuze JF; Preudhomme C; Stratton MR; Alexandrov LB; Padron E; Ogawa S; Koscielny S; Figueroa M; Solary E
    Nat Commun; 2016 Feb; 7():10767. PubMed ID: 26908133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.